Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes

(2018) Bethany T. Samuelson Bannow et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials

(2018) Madan Jagasia et al.   Immunotherapy

Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages

(2018) Marie Febvre-James et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis – Myeloproliferative Disorders Research Consortium 114 study

(2018) Vikas Gupta et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

(2016) Mohamed Shanavas et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cord-Blood Transplantation in Patients with Minimal Residual Disease

(2016) Filippo Milano et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

(2015) M. Deininger et al.   BLOOD

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

(2015) N M Kröger et al.   LEUKEMIA

Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis

(2015) Giovanni Caocci et al.   LEUKEMIA & LYMPHOMA

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis

(2014) Marie Robin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

(2014) T Stübig et al.   LEUKEMIA

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

(2014) A Tefferi et al.   LEUKEMIA

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes

(2013) Andrew R. Rezvani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Scouting out the neighborhood in AIDS-related lymphoma

(2013) K. Dunleavy et al.   BLOOD

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

(2013) N Jaekel et al.   BONE MARROW TRANSPLANTATION

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

(2012) B. L. Scott et al.   BLOOD

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis

(2012) M. Ditschkowski et al.   HAEMATOLOGICA

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis

(2010) S. Takagi et al.   BLOOD

Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT

(2008) Takaaki Konuma et al.   LEUKEMIA RESEARCH